Clinical Trial Update: A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating the efficacy, pharmacokinetics, pharmacodynamics, and safety of CT-P53 versus Ocrevus in relapsing-remitting multiple scl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• CT-P53 (CT-P53)
• Ocrevus (ocrelizumab)

Snippet

Sponsor: Celltrion | Conditions: Relapsing-remitting Multiple Sclerosis | Phase 3 | Status: RECRUITING